Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCaja Costarricense de Seguro Social
About this trial
Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025.
Patients aged 18 years or older, of both sexes.
Patients with at least one dermatological evaluation recorded during the study period.
Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic treatments.
Disqualifiers
Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution.
Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation.
Duplicate or inconsistent records that hinder the correct identification and classification of the patient.
Patients attended outside the established study period.
Trial population
he study population will consist of adult patients (≥18 years) of both sexes with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, and documented in EDUS at the Dermatology Service of Hospital México between January 2019 and December 2025. Patients must have at least one recorded dermatological evaluation during the study period and must have received some form of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic therapies. Patients with insufficient or incomplete clinical records that prevent adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution will be excluded, as well as those with a presumptive diagnosis without histopathological confirmation, duplicate or inconsistent records, patients attended outside the study period, those outside the defined age range, and patients.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Characterize the epidemiology
Characterize the epidemiology of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México.
Time frame
2019-20252
Characterize the therapeutic management
Characterize the therapeutic management of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México
Time frame
2019-2025.Secondary outcomes
1
Describe the sociodemographic/epidemiological characteristics
To describe the sociodemographic and epidemiological characteristics of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México during the period from 2019 to 2025.
Time frame
2019-20252
Classify the clinical manifestations/clinical subtypes
Classify the clinical manifestations and clinical subtypes of cutaneous T-cell lymphoma present in the studied population.
Time frame
2019-20253
Identify the histopathological/ immunohistochemical findings
To identify the histopathological and immunohistochemical findings associated with cutaneous T-cell lymphoma in the included patients.
Time frame
2019-20254
Analyze the therapeutic management modalities.
Analyze the therapeutic management modalities used, including skin-directed therapies and their outcomes.
Time frame
2019-2025Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: